sözaltı news Journal
Journal
EN AZ
These life-saving treatments were considered ‘too small’ to fund. Until now.

These life-saving treatments were considered ‘too small’ to fund. Until now.

bigthink.com 08.09.2026 15:00 36 views
When 10-month-old Noa Greenwood was diagnosed with Canavan, her parents Lee and Lori were confronted with an idea of a future they’d never prepared for. Canavan is a rare, inherited neurodegenerative dis

These life-saving treatments were considered ‘too small’ to fund. View our Twitter (X) feedView our Youtube channelView our Instagram feedView our Substack feedView our Spotify feed These life-saving treatments were considered ‘too small’ to fund. Doctors told Noa Greenwood's family that she wasn't expected to live past age ten.

This new biotech changed that, and opened the doors to a whole new wave of medical funding, treatment, and care. Science and TechInnovationBiotechnologyClinical TrialsBusiness Models These life-saving treatments were considered ‘too small’ to fund. Eric Siegel, Co-Founder & CEO, Gooder AI, argues machine learning (ML) projects go astray because their stakeholders focus too often on the technological fireworks — the “rocket science” of predictive models.

The community healthcare model transforming lives across West Africa American innovators are rewriting cement’s recipe — and its rulebook We’ve been looking for life. Here’s why we should look for intelligence instead Indigenous leadership is essential to climate action. We may find alien life, but will we be able to accept the consequences? 95% of the universe is invisible.

Here’s why that should fill us with wonder. How and why your memories shift over time, explained by neuroscience This one essential trait begins shaping us seconds after birth The ocean is evolving, and it’s not based on the ‘survival of the fittest’ Creativity is essential. Here’s how it can catalyze social justice.

When 10-month-old Noa Greenwood was diagnosed with Canavan, her parents Lee and Lori were confronted with an idea of a future they’d never prepared for. Canavan is a rare, inherited neurodegenerative disease caused by mutations in the ASPA gene. Most children with it never develop beyond the abilities of a six-month-old.

The very day that Noa was diagnosed, a trial for Canavan therapy was posted on clinicaltrials.gov. She was among the first children ever dosed. Within months, she began hitting milestones her parents were told she’d never see.

Extract — continue reading at the source.

Read full story